Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.

Domergue, Camille; Martin, Elodie; Lemarié, Camille; Jézéquel, Pascal; Frenel, Jean-Sebastien; Augereau, Paule; Campone, Mario; Patsouris, Anne.

Afiliação

Domergue C; Medical Oncology Department, ICO Institut de Cancérologie de l'Ouest, 49000 Angers, France.
Martin E; Clinical Trial Sponsor Unit/Biometry, ICO Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France.
Lemarié C; Biopathology Department, ICO Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France.
Jézéquel P; Omics Data Science Unit, ICO Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France.
Frenel JS; Medical Oncology Department, ICO Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France.
Augereau P; Medical Oncology Department, ICO Institut de Cancérologie de l'Ouest, 49000 Angers, France.
Campone M; Medical Oncology Department, ICO Institut de Cancérologie de l'Ouest, 49000 Angers, France.
Patsouris A; Medical Oncology Department, ICO Institut de Cancérologie de l'Ouest, 49000 Angers, France.

Cancers (Basel) ; 14(10)2022 May 19.

Article em En | MEDLINE | ID: mdl-35626113